All In MedTech

Device Trial Radar · NCT07578441

VitaSmart HOPE System: Bridge to HOPE Registry

A Post-market, Multi-center Clinical Registry to Evaluate the Safety, Effectiveness, and Real-World Utilization of the VitaSmart Hypothermic Oxygenated Perfusion (HOPE) System (Bridge to HOPE Registry)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

5,000

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Dec 2028

Study completion Dec 2033

Sponsor

Lead sponsor
Bridge to Life Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
The Cleveland Clinic
First posted
May 11, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a post-market, multicenter, single-arm, observational registry evaluating real-world use of the VitaSmart HOPE System under standard of care conditions. Clinical data from up to 5000 transplant recipients will be included in the registry at up to 20 U.S. transplant centers. This registry will include clinical data collected retrospectively from medical records of recipients already transplanted before the initiation of the registry and any new recipients of livers that meet donor selection criteria. This registry introduces no contact with the transplant recipient and registry participants will follow standard of care. Data will be collected through up to 5 years of standard of care clinical follow-up. This registry represents minimal risk to the transplant recipients being studied. The participants included in this registry will have undergone transplant surgery with a deceased donor liver graft that was perfused using the VitaSmart HOPE System, a medical device that is cleared by the Food and Drug Administration (FDA) for commercial use in the U.S. All perfusions of deceased donor liver grafts will be performed in accordance with standard medical practice. The objectives of this registry is to Evaluate the safety and efficacy of HOPE prior to liver transplantation in real-world clinical settings.

Conditions

  • End Stage Liver DIsease
  • Liver Failure

Interventions

  • hypothermic oxygenated perfusion therapy of a donor liver under standard of care conditionsDevice

    Observational, real-world use of the VitaSmart HOPE System with a donor liver graft under standard of care conditions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Recipients alive with functioning graft at 1-year post-transplantTime frame: 1-year post-transplant

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Georgetown University

    Washington D.C., District of Columbia

  • Cleveland Clinic

    Weston, Florida

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.